McEwan P, Morgan AR, Boyce R, Bergenheim K, et al. The cost-effectiveness of dapagliflozin in treating high risk patients with type
2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58
trial. Diabetes Obes Metab 2020 Dec 28. doi: 10.1111/dom.14308.
PMID: 33368855